On September 29, 2026, the exercise window for outstanding warrants closed. The Company registered aggregate share capital increases of nominal DKK 210,812 through the issuance of 210,812 ordinary shares against average cash consideration of approximately USD $123.36 per share. This increased total share capital to nominal DKK 66,400,738 and amended the articles of association. Ascendis Pharma A/S operates in the biotechnology industry, focusing on the development of therapies for rare diseases.
